Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepolizumab versus placebo to study eosinophil half-life in eosinophilic asthma
NL-OMON45761Active, not recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Jun 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Trial of mepolizumab in eosinophilic asthma (EA) (2 arms), sponsored by University Medical Center Utrecht. Started Jun 2017; status: active, not recruiting.
02
Drugs
mepolizumab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on NL-OMON45761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45761.